
|Articles|September 22, 2022
New Phesi Analysis of Alzheimer’s Patients Highlights Need for Preventative Approach that Includes Younger Participants
Advertisement
Phesi identified 117,463 patients who participated in disease modifying trials; representing a significant portion of the patient population. The Phesi analysis reveals the decline that occurs in Alzheimer’s patients over a single 12-month period, with the average 72-year-old suffering from Alzheimer’s losing 18% of cognitive function (measured by MMSE) in 12 months.
Read more about the analysis
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
2
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
5



